New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities […]

Washington, D.C., Dec. 07, 2025 (GLOBE NEWSWIRE) — A former CIA counter-terrorism officer's recent presentation is urging Americans to understand the full scale of China's military and technological rise, warning that the nation's rapid expansion in artificial intelligence and autonomous weaponry represents a shift with global consequences. According to former national security analyst Buck Sexton,

Former National Security Analyst Signals a Warning in Recent Presentation: “Most Americans are completely uninformed about China's ambition and power.” Buck Sexton Details China's Expanding AI Military Capabilities and Why He Thinks U.S. Officials Are Increasingly Alarmed GlobeNewswire December 07, 2025 Washington, D.C., Dec. 07, 2025 (GLOBE NEWSWIRE) — A former CIA counter-terrorism officer's recent

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public. So What: If you purchased agilon health securities you may be

In addition to meeting the primary endpoint of non-inferiority foroverall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease

(NASDAQ:REGN), All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of greater-than or equal to70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable

(NASDAQ:LYEL), 93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting Manageable safety profile appropriate for

Lynozyfic(TM) (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment GlobeNewswire December 07, 2025 All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of greater-than or equal to70% despite limited

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition GlobeNewswire December 07, 2025 93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large

New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub’s September 2025 initial public offering (the “IPO”), of the important January 23, 2026